HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry.

AbstractBACKGROUND:
There is currently limited experience on the feasibility and efficacy of autologous stem cell transplantation in elderly patients with diffuse large B-cell lymphoma.
DESIGN AND METHODS:
We analyzed the outcome of 2612 patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation between 2000 and 2005 and reported to the European Blood and Marrow Transplantation registry. Four hundred and sixty-three patients (18%) were > or =60 years old at the time of the transplant (median, 63 years). When compared to 2149 patients <60 years old at the time of transplantation, the elderly patients had more frequently received at least two treatment lines (76% vs. 57%, p<0.001), were less commonly in first complete remission at the time of transplantation (23 % vs. 30 %, p=0.005) and received their transplants later after diagnosis (median time 14 months vs.7.5 months, p<0.001).
RESULTS:
Non-relapse mortality was higher in elderly patients at 100 days (4.4 % vs. 2.8 %), at 1 year (8.7% vs. 4.7%) and at 3 years (10.8% vs. 6.5%) (p=0.002). With a median follow-up of 12 months for the surviving patients for the elderly group and 15 months for the younger group, the risk of relapse was 38% and 32%, respectively (p=0.006).The progression-free survival was 51% and 62%, respectively, at 3 years (p<0.001). The overall survival rate was 60% vs. 70%, respectively, at 3 years (p<0.001).
CONCLUSIONS:
Autologous stem cell transplantation is feasible in selected elderly patients with diffuse large B-cell lymphoma, although non-relapse mortality is somewhat higher than in younger patients. Both progression-free and overall survival rates are promising taking into account the generally poorer outcome of elderly patients with diffuse large B-cell lymphoma.
AuthorsEsa Jantunen, Carmen Canals, Alessandro Rambaldi, Gert Ossenkoppele, Bernardino Allione, Didier Blaise, Eulogio Conde, Hervè Tilly, Gordon Cook, Fiona Clark, Andrea Gallamini, Andrew Haynes, Nicolas Mounier, Peter Dreger, Michael Pfreundschuh, Anna Sureda, EBMT Lymphoma Working Party
JournalHaematologica (Haematologica) Vol. 93 Issue 12 Pg. 1837-42 (Dec 2008) ISSN: 1592-8721 [Electronic] Italy
PMID18838474 (Publication Type: Journal Article)
Topics
  • Age Factors
  • Aged
  • Aged, 80 and over
  • Europe (epidemiology)
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Lymphoma, Large B-Cell, Diffuse (mortality, therapy)
  • Middle Aged
  • Registries
  • Survival Analysis
  • Transplantation, Autologous
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: